Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics.

And Denali (Nasdaq: DNLI) is taking a "small" equity stake as well, Tenvie leaders said. What's more, 35-employee Tenvie is subleasing 15,000 square feet from Denali in South San Francisco.

The biotech, called Tenvie Therapeutics, launched Wednesday with $200 million from ARCH Venture Partners — one of Denali’s early investors — as well as F-Prime Capital, Mubadala Capital ...

Tenvie Therapeutics has launched with $200 million and a clutch of assets from Denali Therapeutics to go after neurological diseases with small molecules. Backed by ARCH Venture Partners, F-Prime ...

At 20,310 feet tall, Denali is visible for hundreds of miles around. For thousands of years, it has been called not just Denali but a variety of names by Alaska Native people living around the ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with ... including programs acquired from Denali Therapeutics Inc., with a proven team of research and development leaders.

Today, a brief rundown of news involving Tenvie Therapeutics and Jasper Therapeutics, as well as updates from Sana Biotechnology, Stoke Therapeutics and City Therapeutics that you may have missed.

President Donald Trump signed an executive order Monday renaming Denali—the highest peak in North America—to Mount McKinley, the Alaska mountain’s name prior to 2015, a move he has suggested ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with a commitment to transform the treatment of neurological diseases. The company combines a deep and diverse portfolio of small ...